Keros Therapeutics (KROS) Net Margin (2019 - 2025)
Keros Therapeutics (KROS) reported Net Margin of 4066.03% for Q4 2025, down 1312627.0% on a YoY basis from N/an in Q4 2024, and down 7865.62% quarter-over-quarter from 51.04% in Q3 2025.
Keros Therapeutics (KROS) Net Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Net Margin for 6 years, with the latest figure at 4066.03% in Q4 2025.
- For the quarter ending Q4 2025, Net Margin fell 1312627.0% year-over-year to 4066.03%; the trailing twelve-month figure through Dec 2025 stood at 35.62% (down 15609188.0% YoY), and the FY2025 full-year result was 35.65%, changed N/A from the prior year.
- Net Margin for Q4 2025 stood at 4066.03%, down from 51.04% in the prior quarter.
- The five-year high for Net Margin was 9060.24% in Q4 2024, with the low at 493000.0% in Q3 2023.
- Historically, Net Margin has averaged 49612.82% across 5 years, with a median of 168.96% in 2025.
- Annual changes were most pronounced in 2024 — Net Margin soared 47935155 bps — and 2025, when it slumped 1312627 bps.
- Keros Therapeutics' Net Margin stood at 38.77% in 2021, then sank by 247 bps to 134.37% in 2022, then plunged by 20844 bps to 28141.96% in 2023, then jumped by 132 bps to 9060.24% in 2024, then sank by 145 bps to 4066.03% in 2025.
- The last three Net Margin figures came in at 4066.03% (Q4 2025), 51.04% (Q3 2025), and 168.96% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -4,066.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,066.03% |
| Sep 30, 2025 | -51.04% |
| Jun 30, 2025 | -168.96% |
| Mar 31, 2025 | 70.27% |
| Dec 31, 2024 | 9,060.24% |
| Sep 30, 2024 | -13,648.45% |
| Dec 31, 2023 | -28,141.96% |
| Sep 30, 2023 | -493,000.00% |
| Mar 31, 2022 | -134.37% |
| Dec 31, 2021 | -38.77% |
| Jun 30, 2021 | -15,622.00% |
| Dec 31, 2019 | -128.04% |
| Sep 30, 2019 | -159.96% |
| Jun 30, 2019 | -132.12% |
| Mar 31, 2019 | -145.32% |